Many different types of anti-cancer drugs have been tested on mesothelioma with varying degrees of success. Traditional chemotherapy remains the most effective option. Ongoing clinical trials are investigating other drugs to find more effective medications for mesothelioma.
The different types of anticancer drugs tested against mesothelioma include:
- Targeted therapy
- Photodynamic therapy
- Hormone therapy
Any anticancer drug is technically considered a form of chemotherapy. The difference between traditional chemotherapy and other anti-cancer drugs is that chemotherapy kills cancer cells while others block cancer cells from growing or spreading.
The two most effective chemotherapy drugs for mesothelioma cancer, cisplatin and pemetrexed, are the only two drugs approved by the U.S. Food and Drug Administration (FDA) to treat mesothelioma. Patients who wish to try other drugs may do so through clinical trials and compassionate-use programs.
These medications may be used in combination with treatments such as surgery and radiation therapy. This combination approach, called multimodal therapy, attacks the cancer in multiple ways for the best chance of killing cancer cells and shrinking tumors.
The most common chemotherapy medications for mesothelioma include:
Chemotherapy is one of the most common treatments for any cancer, including mesothelioma. Chemotherapeutic agents seek out and attack cells, including cancer cells, which are rapidly dividing. In spite of its well-known side effects, chemotherapy is considered one of the best mesothelioma treatment options.
A combination of the chemotherapy drugs cisplatin and pemetrexed has proven most effective for the majority of mesothelioma patients. This combination is the most common first-line chemotherapy for people with mesothelioma. If the drugs aren’t tolerated well or aren’t highly effective, second-line chemotherapy may be recommended. Second-line chemotherapy drugs include carboplatin, gemcitabine, vinorelbine (Navelbine) or doxorubicin.
Most chemotherapy drugs are synthetic, but Navelbine is actually semi-synthetic. Part of the drug is extracted from a flowering plant known as periwinkle. Navelbine may be administered alone or in combination with another chemotherapy drug such as cisplatin.
Common Side Effects of Chemotherapy Drugs
Doctors say the most typical side effects of mesothelioma chemotherapy drugs include:
- Hair Loss
- Impaired vision or hearing
These are powerful drugs that may disrupt digestion. Some patients report stomach pain, nausea and irregular stools. Medications are available to control these side effects. Because of the potency of these drugs, a patient who develops a fever, chills, rash, swollen ankles and blood in their urine should immediately contact their physician.
Free Mesothelioma Nutrition Guide
Eating right and balancing your diet while undergoing chemotherapy can help ease your symptoms.Get Free Recipes & Tips
Immunotherapy agents are used to enhance a patient’s own immune system and help the body to attack cancer cells. The immune system often does not recognize cancer cells as unhealthy cells. But with the addition of immunotherapy medications, the immune system may better recognize the difference between healthy cells and cancerous cells, and begin fighting the cancer.
Interferons and interleukin-12 are also immunomodulatory agents that have been studied for the treatment of malignant mesothelioma.
CRS-207 is an immunotherapy vaccine derived from a bacterium that is producing impressive results in a phase I mesothelioma trial. Preliminary results became available in 2016 that showed 94 percent of participants responded to the drug. Tumor shrinkage happened for 85 percent of participants and 35 percent saw no new tumor growth. Clinical trials of CRS-207 in mesothelioma are ongoing and promising.
Amatuximab (also known as MORAb-009) is an immunotherapy drug that was tested on mesothelioma patients in phase I and II clinical trials. Despite promising results in the phase I trial, the phase II trial showed that not enough mesothelioma patients responded to the drug to warrant further study. The overall median survival was 14.8 months.
Andy A. Pleural mesothelioma survivor and amatuximab patient diagnosed in 2010
“I guess I’m an anomaly. I’m doing great right now. I really am. I don’t look like a stage 4 cancer patient.”
The drug SS1(dsFv)-PE38, which is also known as SS1P, is an immunotoxin. This type of drug combines immunotherapy’s tumor-honing properties with a toxin so that it specifically targets cancer cells and then kills them. To date, an ongoing phase I study of SS1P in people with pleural mesothelioma has reported a partial tumor response in 12 out of 20 participants.
In addition to their ability to recruit the immune system in the fight against cancer, immunotherapy drugs are appealing because they have milder side effects than chemotherapy.Learn more about immunotherapy
Targeted Therapy Drugs
Targeted therapy is a growing field in cancer treatment that targets specific molecular changes involved in cancer cell development, growth, metastasis and death. While chemotherapy affects healthy and cancerous cells, targeted therapy is designed to only affect cancerous cells.
NGR-hTNF is a targeted therapy drug that is currently in phase III trials to determine its efficacy as a management therapy for people with recurring mesothelioma. In the phase II trial, overall survival was 12 months among patients formerly treated with pemetrexed chemotherapy. The phase III trial is ongoing and current data shows an overall survival of 11.7 months among certain patients. This preliminary data offers hope for more effective second-line therapy for recurring mesothelioma that will buy patients more time.
This targeted drug blocks heat shock protein 90, a protein that promotes mesothelioma cell growth. A phase I and II clinical trial of ganetespib in pleural mesothelioma patients is ongoing in the U.K. The trial is testing ganetespib as an ongoing maintenance therapy after combination treatment with ganetespib and chemotherapy.
This drug targets EZH2, an enzyme that helps mesothelioma cancer cells to grow and divide. The drug seems to work best in patients with the BAP-1 gene mutation, which is present in 60 percent of mesothelioma cases. Two clinical trials are investigating tazemetostat in mesothelioma patients. The first accepts participants with or without the BAP-1 mutation. The second only includes mesothelioma patients with a BAP-1 mutation.
Another form of targeted therapy that was tested in clinical trials on mesothelioma patients is the drug ranpirnase (Onconase). The drug is among the few therapies that progressed all the way to a phase III clinical trial. Though early results were promising, preliminary phase IIIb clinical trial results showed that Onconase did not improve overall survival enough for the FDA to award approval.
Following the Onconase trials, mesothelioma researchers — among them Dr. Michele Carbone and Dr. Harvey Pass — performed a study on mesothelioma cell lines in 2011 to see whether Onconase could be more effective in mesothelioma patients with low levels of the protein kinase enzyme Akt. Results from the study suggest that Onconase could provide slight therapeutic benefit to that group, though no further studies have been conducted to investigate this potential in humans.
Another study tested the combination of Onconase and an anti-malarial drug in test tubes and in mice with mesothelioma. This 2016 Chinese study showed a significant decrease in tumors and an anti-angiogenesis effect. Further research is necessary to test this effect in humans.
Scientists continue the search for effective drugs to help prevent angiogenesis, a normal function that allows the body to heal itself by creating new blood vessels. The process also builds vessels to tumors, feeding them with a fresh supply of blood and allowing them to grow and spread.
Researchers believe that stopping this process may be the key to stopping the aggressive nature of mesothelioma, not to mention the spread of many other types of cancer. Angiogenesis also is a necessary precursor to metastasis, which is the process of cancer cells spreading from one area of the body to another.
Drugs that could inhibit the formation of new blood vessels to tumors are called anti-angiogenesis drugs or angiogenesis inhibitors. An example of an anti-angiogenesis agent is bevacizumab. Without blood vessels to bring nutrients, the cancer cells are unable to divide and spread, and eventually die. Stopping angiogenesis is not the hard part. The hard part is stopping angiogenesis related to cancer without hindering the body’s natural ability to heal itself. This is extremely difficult and is at the center of considerable research.
Combined with other treatments, such as chemotherapy and radiation, angiogenesis inhibitors are extending life among certain mesothelioma patients in clinical trials. They don’t seem to work consistently in everyone, but some mesothelioma patients have lived years longer because of these drugs. For example, Avastin, thalidomide, sorafenib and cediranib have improved survival rates for certain mesothelioma patients in clinical trials.
Prior studies of Avastin, also known as bevacizumab, in mesothelioma clinical trials produced inconsistent results among participants. Some patients responded well, others not at all. However, a 2015 French study tested the drug on hundreds of mesothelioma patients in combination with chemotherapy and reported an overall survival of 18.8 months. Average survival is around 12 months with chemotherapy alone.
Get a Free 2020 Mesothelioma Treatment Guide
Our guide includes free treatment information, mesothelioma books and wristbands, delivered overnight.Get Your Free Guide
How Do These Drugs Work?
Angiogenesis occurs by means of a complex “signaling cascade” in which cells communicate messages via proteins. Anti-angiogenesis drugs interfere with this process in one of three ways, each corresponding to a specific step of the cascade. This class of drugs is technically considered a form of targeted therapy.
The first step of the angiogenesis process makes room for new endothelial cells, which are located on the outer lining of blood vessels. In this step, endothelial cells break down placeholder material, called the extracellular matrix, surrounding the cells.
Cancer cells trigger this process to create space for a new blood vessel to branch off an existing one toward a tumor. When anti-angiogenesis drugs inhibit this process, new cells have no room to form blood vessels, preventing the angiogenesis cascade.
Side Effects of Anti-Angiogenesis Drugs
Anti-angiogenesis drugs tend to cause fewer and milder side effects than chemotherapy. Whereas chemotherapy drugs attack quickly dividing cells even if they are healthy, anti-angiogenesis drugs don’t affect most healthy cells.
The downside is that because angiogenesis occurs when wounds are healing, these drugs complicate the healing process and may lead to excessive bleeding. Patients may also develop blood clots in the arteries, internal bleeding or a hole in the digestive tract.
Overall, angiogenesis-targeting therapies have a low risk of major side effects, while showing good results in preventing mesothelioma metastasis.
Photodynamic Therapy Drugs
Photodynamic therapy is a two-step treatment procedure that uses photosensitizing drugs to make cancer cells vulnerable to light and then uses light to destroy the cancer cells. For mesothelioma patients, the photosensitizer is almost always porfimer sodium (Photofrin), which is also used in other cancers like esophageal cancer.
Researchers are testing photodynamic therapy in pleural mesothelioma patients and discovered it improved survival times. The treatment is still in development for peritoneal mesothelioma while doctors search for an effective means of administering light to the abdominal cavity. The treatment commonly causes light sensitivity for about six weeks, which may result in burning, swelling or scarring.
The Future of Mesothelioma Drugs
The landscape of new mesothelioma treatments is constantly evolving.
Oncologists say the future of all cancer treatment is personalization. The one-size-fits-all approach is a thing of the past. In the future, doctors will examine your genes, the DNA in your tumors and biomarkers in your blood to decipher which drugs will directly target your cancer.
To get there, mesothelioma clinical trials need more participants. Consider speaking with your oncologist about which trials are right for you.
Karen F. peritoneal mesothelioma survivor diagnosed in 2015
“Mesothelioma can be a frightening reality to be faced with. The chance of recovery may seem grim…But do not give up on life. You still can get through with a faith in God.”
6 Cited Article Sources
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
Hassan, R. et al. (2014, December). Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/25231400
Jahan, T. et al. (2016, April). 208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial.
Retrieved from: http://www.jto.org/article/S1556-0864(16)30330-6/fulltext
Gaafar, R. et al. (2015). Phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma.
Retrieved from: http://www.molmed.com/sites/default/files/uploads/publications/2688/ngr015_asco_2015_abs_7501_oral.pdf
Epizyme. (2017). Study of the EZH2 inhibitor tazemetostat in malignant mesothelioma.
Retrieved from: https://clinicaltrials.gov/ct2/show/NCT02860286
Zalcman, G., et al. (2016). Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study: a randomized, controlled, open-label, phase 3 trial.
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/26719230
- Bronte, G. et al. (2016). The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? Retrieved from: http://www.croh-online.com/article/S1040-8428(16)30191-3/fulltext#sec0020
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified January 6, 2020